Table 3. One and three-year transplant outcomes by ART regimen ^°.

	N (%)	Patient survival				Death-censored graft survival †				Biopsy-proven acute rejection				Severe infection †
		1y	p	3y	p	1y	p	3y	p	1y	p	3y	p	6m	p
Overall	58	91.4		89.7		93.1		89.7		13.8		17.2		26.3
TDF
Yes	19	89.5		89.5		94.7		94.7		15.8		10.5		31.6
No *	35	94.3	0.6	91.4	>0.99	91.4	>0.99	85.7	0.4	14.3	>0.99	22.9	0.4	23.5	0.52
NRTI
Yes	54	92.6		90.7		92.6		88.9		14.8		18.52		26.4
No	4	75	0.3	75	0.36	100	>0.99	100	>0.99	0	>0.99	0	>0.99	25
NNRTI
Yes	14	100		100		92.9		92.9		7.14		21.4		7.14
No	44	88.6	0.32	86.4	0.32	93.2	>0.99	88.6	>0.99	15.9	0.66	15.9	0.69	32.6	0.08
PI
Yes	33	84.5		81.8		87.9		81.8		21.2		18.2		39.4
No	25	100	0.06	100	0.03	100	0.12	100	0.03	4	0.12	16	>0.99	8.33	0.01
INSTI
Yes	24	95.8		95.8		100		100		8.33		8.33		21.7
No	34	88.2	0.39	85.3	0.38	88.2	0.13	82.4	0.04	17.7	0.45	23.5	0.17	29.4	0.5
Two drug regimens ˆ
NRTI + INSTI	12	100		100		100		100		8.3		8.3		18.1
NRTI + NNRTI	9	100		100		100		100		0		11.1		0
NRTI + PI	23	82.6	0.16	78.3	0.1	86.9	0.41	78.3	0.1	21.7	0.36	21.7	0.65	39.1	0.07
NRTI + other *	21	100		100		100		100		4.8		9.5		10
NRTI + PI	23	82.6	0.11	78.3	0.05	86.9	0.23	78.3	0.05	21.7	0.19	21.7	0.42	39.1	0.04

ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; TDF, tenofovir disoproxil fumarate.

^ºRefers to the ART regimen the patient was discharged home with after the initial transplant hospitalization.

P values correspond to Fisher 's exact test. Numbers in bold represent statistical significance.

^†As defined previously ⁴. See main text for details.

ˆRegimens listed here were three most common ART regimens post-transplant in this cohort.

*Includes NRTI + INSTI and NRTI + NNRTI.